TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akari Therapeutics ( (AKTX) ) has issued an announcement.
On November 24, 2025, Akari Therapeutics received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has until May 25, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. If compliance is not regained, Akari may qualify for an additional 180-day compliance period or face potential delisting, with options to appeal. The company is considering strategies to address the issue, including a possible ratio change of its American Depositary Shares.
The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare and orphan diseases.
Average Trading Volume: 341,385
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.55M
For detailed information about AKTX stock, go to TipRanks’ Stock Analysis page.